Yichao Medical Receives Dual National Endorsements: NMPA Innovative Device Designation and National Key R&D Program

On November 28, 2025, the “Bipolar High-Frequency Ultrasound Dual-Output Surgical Device,” independently developed by Shanghai Yichao Medical Devices Co., Ltd. (Yichao Medical), successfully passed the special review for innovative medical devices conducted by the National Medical Products Administration (NMPA). This marks another national-level authoritative recognition for the product, following its inclusion in the National Key R&D Program in 2022. It not only signifies that the device has officially entered an accelerated pathway to market launch but also demonstrates its industry-leading position in terms of technology, clinical application, and market potential. The product is currently undergoing clinical trials.

This surgical device stands out by innovatively addressing the scientific challenge of dynamically mixing and modulating different energy output ratios based on tissue characteristics, achieving two breakthrough technological innovations that demonstrate the company’s exceptional technical prowess.

● Tissue Intelligent Recognition Technology

Pioneered the study of the relationship between tissue impedance and energy response across different tissue types, enabling intelligent tissue identification and dynamic adjustment of mixed energy levels through a human tissue “impedance analysis model + energy response curve” framework.

● Precision Energy Control Technology

Pioneering the “Operating Room Master Unit” based on a “Modular Technology Architecture Foundation,” it features three core underlying technologies: millisecond-level switching and energy fusion of dual energies, independent detection of dual signals with energy feedback excitation, and hybrid-energy anti-interference with signal filtering processing. This resolves the issue of mutual interference when different energy sources are activated simultaneously and dynamically adjusted.

The product can automatically switch between dual-energy modes and deliver hybrid output based on tissue characteristics, intelligently adapting its operational mode to different clinical scenarios. It enables seamless transitions among various device types, including electrosurgical units, ultrasonic scalpels, and multimodal energy hybrid systems, truly realizing “intelligent, on-demand device versatility.”

The product disrupts traditional clinical surgical procedures, effectively reducing the time gaps caused by frequent instrument switching during surgery and the associated surgical risks. Preliminary study results show that, while maintaining excellent control of thermal injury, the product’s cutting speed is 30% higher and its hemostatic efficacy is 20% better than those of leading international products, demonstrating superior performance. Meanwhile, the automatic switching between product types effectively reduces the variety and quantity of consumables used, lowers health insurance expenditures, and offers significant economic value and market potential.

Leveraging its robust core technology architecture and the “Operating Room Master Machine,” Shanghai Yichao Medical Devices has built a comprehensive product portfolio covering all operating room scenarios, and pioneered the “Technology Asset Sharing” business model to provide product-level solutions for the industry.

Currently, the company’s core products have been technologically adopted by multiple leading enterprises both domestically and internationally and have obtained regulatory approvals. Furthermore, these products have gained recognition from numerous hospitals across China, which not only validates the success of this business model but also confirms the certainty and stability of future market sales.

Looking ahead, Shanghai Yichao Medical Devices will continue to leverage technological innovation as its engine and clinical needs as its guide. By relying on its full-chain independent innovation capabilities and a rich product portfolio, the company will consistently lead Chinese-made medical devices toward high-end and intelligent development, achieving overtaking on the straightaway in the medical device industry through original Chinese innovations.

Shanghai Yichao Medical Devices Co., Ltd. is an innovative medical device R&D and manufacturing company with core underlying technologies, focusing on a full range of surgical medical devices for operating rooms, with product portfolios covering energy-based surgery, ultrasound-guided interventions, and surgical robots.

In 2022, as the lead institution, the original "Intelligent Dual-Engine Dynamic Hybrid Energy Surgical System" was approved for the National Key R&D Program.

In 2024, as the lead institution, the “Real-Time Adaptive Intelligent Diagnosis and Treatment Integrated System for Ureteroscopic Lithiasis” was approved under the National Key R&D Program and entered the NMPA’s priority review green channel;

Won the First Prize in the Finals of the 6th China Medical Device Innovation and Entrepreneurship Competition in 2023.

Qingdao Jianxin Medical Technology Co., Ltd., a group company, leverages its “Energy Surgery Master Platform” as the technological foundation to provide comprehensive, product-level surgical solutions for operating rooms. By adopting a “Technology Asset Sharing” model, it has established a “Product Supermarket and Technology Bank” to facilitate technology transfer and secure product sales.

The company has repeatedly been awarded national-level research projects and first prizes in national innovation competitions. It currently holds 125 patents, including 48 invention patents, and has established four major product systems: original green-channel innovative products, active minimally invasive surgical devices, passive minimally invasive surgical devices, and conventional minimally invasive surgical instruments. These encompass a comprehensive series of surgical solutions with over 200 product specifications.